SCHEDULE 13G: Vanguard Group Discloses 5% Passive Stake in Capricor Therapeutics Inc.

The Vanguard Group has filed a Schedule 13G, disclosing a passive 5% ownership stake in Capricor Therapeutics Inc. as of December 31, 2024.

Summary

• The Vanguard Group reported a 5% passive ownership stake in Capricor Therapeutics Inc.
• As of December 31, 2024, The Vanguard Group beneficially owned an aggregate of 2,276,784 shares of Capricor Therapeutics Inc. Common Stock.
• The reported ownership represents 5% of the class of securities.
• The Vanguard Group holds 0 shares with sole voting power, 70,929 shares with shared voting power, 2,166,185 shares with sole dispositive power, and 110,599 shares with shared dispositive power.
• The filing was made under Rule 13d-1(b), indicating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 6

Explanation: The filing indicates a significant passive stake by a major institutional investor, which can be viewed as a positive signal of confidence in the company, although it does not imply active engagement in management or strategy.

Positives

• The disclosure of a 5% passive stake by The Vanguard Group, a prominent institutional investor, may be interpreted by the market as a vote of confidence in Capricor Therapeutics Inc.

Risks

• The filing explicitly states that The Vanguard Group's acquisition and holding of shares are for passive investment purposes, not to change or influence control of Capricor Therapeutics Inc., which means they will not actively engage in corporate governance or strategic decisions.

Future Outlook

NA

Management Comments

• The Vanguard Group, through its Head of Global Fund Administration, Ashley Grim, certified that the securities were acquired and are held in the ordinary course of business and not for the purpose or with the effect of changing or influencing the control of Capricor Therapeutics Inc.

Industry Context

NA

Stakeholder Impact

• Shareholders: Disclosure of a significant institutional investor's stake can provide reassurance and potentially influence market perception.

Key Dates

Keywords

Capricor Therapeutics Inc, Vanguard Group, Schedule 13G, Common Stock, Beneficial Ownership, Institutional Investor, Passive Investment, SEC Filing